NEW YORK (GenomeWeb News) – Molecular Response today announced a joint research and development deal with Scripps Genomic Medicine targeting oncology and cardiovascular disease.
The deal calls for Molecular Response to fund up to two discovery programs in the two indications. In return, Scripps will grant the San Diego-based firm exclusive intellectual property rights.
Further financial and other terms of the agreement were not disclosed.
Scripps Genomic Medicine is a division of Scripps Translational Science Institute and Scripps Health.
In a statement, Molecular Response said that the agreement will result in the sharing of technologies and knowledge that will increase the partnership's overall research activities.